Last week’s hot topic on Cystic Fibrosis titled Potential Cystic Fibrosis Therapy Gets FDA Fast Track Approval, Clinical Tests to Follow was written by Carolina Henriques.
The article is focused on the announcement by Proteostasis Therapeutics, Inc., that it recently received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for PTI-428, an investigational oral treatment for cystic fibrosis (CF).
PTI-428 is an oral modulator in the amplifier class. The designation may make the drug eligible for priority review later on.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?